Glaxosmithkline LLC v. Banner Pharmacaps, Inc.
744 F.3d 725
Fed. Cir.2014Background
- GSK sued multiple generic manufacturers under 35 U.S.C. § 271(e)(2) asserting infringement of U.S. Patent No. 5,565,467, which claims dutasteride and “pharmaceutically acceptable solvates” thereof; defendants stipulated to infringement.
- The only independent claim covers dutasteride or a pharmaceutically acceptable solvate; dependent claims recite formulations containing the compound.
- District court construed “solvate” to mean a complex of dutasteride with a solvent formed by reaction, precipitation, or crystallization (not necessarily crystalline); parties disputed whether “solvate” requires crystallinity.
- Defendants challenged validity on written-description (solely pursued on appeal), anticipation, lack of utility, and enablement; the district court rejected all challenges after a bench trial.
- The district court found the specification describes solvates by structure and process (example dissolving dutasteride in propylene glycol) and that a skilled artisan could make and test solvates routinely; it concluded the written description adequately supports the claimed solvates.
- On appeal, the Federal Circuit affirmed, holding the specification’s structural-and-process description matches the claim scope and satisfies the written-description requirement under § 112(a).
Issues
| Issue | Plaintiff's Argument (GSK) | Defendant's Argument (collective) | Held |
|---|---|---|---|
| Whether the written description adequately supports claims to “solvates” of dutasteride | Specification describes solvates by structural composition and formation processes; thus it conveys possession of the claimed genus | Specification fails to describe the crystalline (or broader range of) solvates claimed, so claims lack adequate written description | Affirmed: written description adequate because it identifies structural features and processes matching claim scope |
Key Cases Cited
- Ariad Pharm., Inc. v. Eli Lilly & Co., 598 F.3d 1336 (en banc) (written-description legal standard; requirement of conveying possession)
- Regents of the Univ. of California v. Eli Lilly & Co., 119 F.3d 1559 (structural description suffices to identify genus)
- Fiers v. Revel, 984 F.2d 1164 (identifying conception and limits of functional claiming)
- Amgen, Inc. v. Chugai Pharm. Co., 927 F.2d 1200 (identification by method of preparation relevant to conception)
- Eli Lilly & Co. v. Teva Pharm. USA, Inc., 619 F.3d 1329 (distinguishing claims that require post-formulation properties)
- Boston Scientific Corp. v. Johnson & Johnson, 647 F.3d 1353 (insufficiency where structural characteristics absent)
- Carnegie Mellon Univ. v. Hoffmann-La Roche Inc., 541 F.3d 1115 (written-description pitfalls for functionally defined genetic claims)
- Pozen Inc. v. Par Pharm., Inc., 696 F.3d 1151 (standard of review for factual findings after bench trial)